The Cell Growth and Differentiation (CGD) Program serves the Purdue University Center for Cancer Research as the central component for basic discovery in cancer cell biology. Since the last competitive renewal, membership in the program has grown from 17 to 26 members and includes 10 new, cancerfocused Assistant Professors and the new Center Director. United by a common goal to understand the molecular mechanisms governing the growth of cancer cells, CGD members are drawn from 7 Departments and 5 colleges from across the Purdue campus. The CGD Program has a strong record of publication, producing 260 papers since 2003 (12% collaborative). Program members attract approximately 6.5 million dollars of total peer-reviewed support per year, with 56% percent of the grants and 50% of the dollars awarded from the NCI, the Susan G. Komen Foundation, or the DOD breast and prostate cancer research programs. Those statistics reflect a 35% increase in cancer research dollars since the last competitive review. The CGD Program is structured around three major themes of discovery. Historically, the cornerstone of the CGD program has been its strength in cellular signaling with a distinguished group of senior and junior faculty. Many of these projects have spawned highly productive inter-programmatic collaborations involving members of the Chemistry and Structural Biology and Medicinal Chemistry Programs. The second discovery cluster encompasses the largest number of program participants and is focused on the control of gene expression in cancer cells. There is a growing emphasis on epigenetics and the role of chromatin modifications in gene silencing, which complements the focus of on tissue-specific transcription factors important in growth control decisions and development. The third discovery cluster, in which "Animal Models of Cancer Development" is the theme, forms the newest and fastest growing area within the CGD Program.
The program brings together scientists from various fields to address important cancer-related questions. Program leadership sets goals and encourages collaborations. Through the collaborative interactions important discovery are made, which will aid in reducing the pain and suffering caused by cancer.
|Krisenko, Mariya O; Cartagena, Alexander; Raman, Arvind et al. (2015) Nanomechanical property maps of breast cancer cells as determined by multiharmonic atomic force microscopy reveal Syk-dependent changes in microtubule stability mediated by MAP1B. Biochemistry 54:60-8|
|Cho, Eun Jung; Sun, Bo; Doh, Kyung-Oh et al. (2015) Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. Biomaterials 37:312-9|
|Bai, Yu; Davis, Dexter C; Dai, Mingji (2014) Synthesis of tetrahydropyran/tetrahydrofuran-containing macrolides by palladium-catalyzed alkoxycarbonylative macrolactonizations. Angew Chem Int Ed Engl 53:6519-22|
|Chao, Chi-Hong; Chang, Chao-Ching; Wu, Meng-Ju et al. (2014) MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest 124:3093-106|
|Lee, Kyuwan; Cui, Yi; Lee, Luke P et al. (2014) Quantitative imaging of single mRNA splice variants in living cells. Nat Nanotechnol 9:474-80|
|Yang, Yang; Haskins, Christopher W; Zhang, Wandi et al. (2014) Divergent total syntheses of lyconadins A and C. Angew Chem Int Ed Engl 53:3922-5|
|Ghosh, Arun K; Osswald, Heather L (2014) BACE1 (?-secretase) inhibitors for the treatment of Alzheimer's disease. Chem Soc Rev 43:6765-813|
|Byun, Alexander J; Hung, Kenneth E; Fleet, James C et al. (2014) Colon-specific tumorigenesis in mice driven by Cre-mediated inactivation of Apc and activation of mutant Kras. Cancer Lett 347:191-5|
|Emmert, Dana; Campos, Christopher R; Ward, David et al. (2014) Reversible dimers of the atypical antipsychotic quetiapine inhibit p-glycoprotein-mediated efflux in vitro with increased binding affinity and in situ at the blood-brain barrier. ACS Chem Neurosci 5:305-17|
|Hrycyna, Christine A; Summers, Robert L; Lehane, Adele M et al. (2014) Quinine dimers are potent inhibitors of the Plasmodium falciparum chloroquine resistance transporter and are active against quinoline-resistant P. falciparum. ACS Chem Biol 9:722-30|
Showing the most recent 10 out of 109 publications